Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a intravitreal implant for intravitreal use. It treats diabetic macular edema and non‑infectious posterior uveitis in adult patients.

GNH USA supplies Iluvien as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iluvien (fluocinolone acetonide) is used to manage ocular conditions characterized by inflammation and vascular leakage.

- Diabetic macular edema: reduces retinal swelling and improves visual acuity in patients with chronic DME. - Non‑infectious posterior uveitis: controls intra‑ocular inflammation and helps preserve vision in affected eyes.

Iluvien may be associated with ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Increased intraocular pressure: elevation that may require monitoring or treatment. - Cataract formation: progressive lens opacity observed over time. - Floaters: perception of moving spots in the visual field. - Vitreous opacities: clouding of the vitreous body.

Serious or Rare Side Effects: - Endophthalmitis: intraocular infection requiring urgent intervention. - Retinal detachment: separation of retinal layers that can threaten vision. - Persistent macular edema: worsening swelling despite therapy. - Implant migration: displacement of the device from the intended site.

Before initiating Iluvien therapy, clinicians should consider several precautionary measures to minimize risk. - Intraocular pressure monitoring: measure IOP regularly, especially in glaucoma patients. - Cataract assessment: evaluate lens status before and during treatment. - Prior ocular surgery: defer implantation if recent intraocular surgery has been performed. - Systemic corticosteroid use: assess cumulative steroid exposure to avoid excess effects. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep the implant device in its original packaging, protect from moisture and direct sunlight.

Fluocinolone acetonide can interact with other agents that affect intraocular pressure or systemic steroid metabolism.

Major Interactions (Avoid): - Antiglaucoma medications: concurrent use may be insufficient to control IOP rise. - Systemic CYP3A4 inhibitors: may increase systemic exposure if any drug is absorbed. - Other intravitreal steroids: additive risk of pressure elevation and cataract.

Moderate Interactions (Monitor Closely): - Topical ocular NSAIDs: may alter inflammation control, monitor response. - Systemic immunosuppressants: potential additive immunosuppression, watch for infection. - Anticoagulants: increased risk of intraocular hemorrhage during implantation.